Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456596 | 0.83 | TSHR (0.32) | — | |
| SCHEMBL12915444 | 0.83 | NOS3 (0.33) | HPGDS | |
| SCHEMBL23456655 | 0.81 | CCR1 (0.32) | HMGCR | |
| SCHEMBL1973219 | 0.74 | ADRB1 (0.39) | HMGCR | |
| SCHEMBL12948520 | 0.74 | CCR1 (0.41) | — | |
| SCHEMBL22521384 | 0.72 | KDM4E (0.43) | — | |
| SCHEMBL11465342 | 0.72 | NOS2 (0.39) | — | |
| SCHEMBL19000988 | 0.72 | PDE2A (0.32) | PDE2APDE10A | |
| SCHEMBL10265563 | 0.71 | CHRNA7 (0.36) | HMGCR | |
| SCHEMBL23896790 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161887-A1 | Novel Hydrazone Derivatives For Preventing Or Treating EBV-Related Cancers | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161887-A1 | Novel Hydrazone Derivatives For Preventing Or Treating EBV-Related Cancers | RB1, MALT1, NR3C1 | HPGDS 3064/4885HMGCR 2234/4885PDE2A 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.